Background: No previous study was done to estimate the prevalence of diabetic neuropathy (DN) in Arabic countries. The aim of this study was to estimate the prevalence of DN and its characteristics in Qena governorate. Material and Methods: This is a random sampling of 10 study areas, involving 9,303 inhabitants; 51.1% men and 48.9% women were recruited. There were 57.3% urban residents and 42.7% rural residents. Patients were diagnosed using a screening questionnaire for diabetes mellitus (DM) as well as for DN in addition to measuring blood sugar in suspected cases. All positive cases were referred to Qena University Hospital and were subjected to full clinical, electrophysiological and laboratory investigations. Results: Out of 9,303 people screened, 837 were diabetic giving prevalence 8.99% of the population. Eight hundred eleven had type II DM and 26 cases had type I giving prevalence of 8.7 and 0.3%, respectively. One hundred fifty-five out of 837 (18.5%) diabetic patients had evidence of DN with prevalence rate being 1.7% of the total population. Diabetic polyneuropathy was the commonest type with prevalence 1.5%. The prevalence of DN was higher in women than in men. Rural residents had significantly higher prevalence of DN compared to urban residents (1.9 vs. 1.4) and illiterate population more than educated (5.8 vs. 1.2). Conclusion: The overall crude prevalence rate of DM and DN is nearly the same as in European countries and lower than that in other Arabic countries.

1.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-149.
2.
Herman WH, Ali MA, Aubert RE, Engelgau MM, Kenny SJ, Gunter EW, Malarcher AM, Brechner RJ, Wetterhall SF, DeStefano F, et al: Diabetes mellitus in Egypt: risk factors and prevalence. Diabet Med 1995;12:1126-1131.
3.
Pambianco G, Costacou T, Strotmeyer E, Orchard TJ: Risk factor associations with clinical distal symmetrical polyneuropathy and various neuropathy screening instruments and protocols in type 1 diabetes. Diabetes Res Clin Pract 2011;91:e15-e20.
4.
Baba M: Hyperesthesia: an early manifestation of diabetic polyneuropathy. Intern Med 2002;41:1079-1080.
5.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group: Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285-2293.
6.
Vinik A, Ullal J, Parson HK, Casellini CM: Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006;2:269-281.
7.
Akbar DH, Mira SA, Zawawi TH, Malibary HM: Subclinical diabetic neuropathy: a common complication in Saudi diabetics. Saudi Med J 2000;21:433-437.
8.
Kadiki OA, Roaed RB: Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J 1999;5:6-13.
9.
Saadi H, Carruthers SG, Nagelkerke N, Al-Maskari F, Afandi B, Reed R, Lukic M, Nicholls MG, Kazam E, Algawi K, Al-Kaabi J, Leduc C, Sabri S, El-Sadig M, Elkhumaidi S, Agarwal M, Benedict S: Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract 2007;78:369-377.
10.
Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-1486.
11.
Sinnreich M, Taylor BV, Dyck PJ: Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist 2005;11:63-79.
12.
El-Shazly M, Abdel-Fattah M, Zaki A, Bedwani R, Assad S, Tognoni G, Nicolucci A: Health care for diabetic patients in developing countries: a case from Egypt. Public Health 2000;114:276-281.
13.
Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, Herman WH: The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996;13:337-340.
14.
Arafa NA, Amin GE: The epidemiology of diabetes mellitus in Egypt: results of a national survey. Egypt J Commun Med 2010;28:29-43.
15.
Abdo NM, Mohamed ME: Effectiveness of health education program for type 2 diabetes mellitus patients attending Zagazig university diabetes clinic, Egypt. J Egypt Public Health Assoc 2010;85:113-130.
16.
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA: A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289.
17.
World Health Organization: Report on the second regional meeting on diabetes prevention and control. Muscat-Oman, EMRO (WHO-EM/DIA/8/E/L), 1997.
18.
International Diabetes Federation: IDF Diabetes Atlas: International Diabetes Federation, ed 5, 2011. http://www.idf.org/diabetesatlas.
19.
Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ: Prevalence of diabetic complications in relation to risk factors. Diabetes 1986;35:1332-1339.
20.
Walters DP, Gatling W, Mullee MA, Hill RD: The prevalence of diabetic distal sensory neuropathy in an English community. Diabet Med 1992;9:349-353.
21.
Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, Mohan V: Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55). Diabet Med 2008;25:407-412.
22.
Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1479-1486.
23.
Bharucha NE, Bharucha AE, Bharucha EP: Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991;41:1315-1317.
24.
Savettieri G, Rocca WA, Salemi G, Meneghini F, Grigoletto F, Morgante L, Reggio A, Costa V, Coraci MA, Di Perri R: Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1993;43:1115-1120.
25.
MacDonald BK, Cockerell OC, Sander JW, Shorvon SD: The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123:665-676.
26.
Kandil MR, Darwish ES, Khedr EM, Sabry MM, Abdulah MA: A community-based epidemiological study of peripheral neuropathies in Assiut, Egypt. Neurol Res 2012;34:960-966.
27.
Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ: Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care 2011;34:2220-2224.
28.
Bouhassira D, Hartemann A, Letanoux M: Prevalence of neuropathic pain in diabetic patients: a French cross-sectional study. Eur J Pain Suppl 2011;5:161.
29.
Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ: Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21:976-982.
30.
La Cesa S, Truini A, Leonetti F, Jann S, Franceschini LDT, Zanette G, et al: Prevalence of peripheral neuropathies and neuropathic pain in patients with diabetes. Preliminary results of an Italian mulitcentre study. Eur J Neurol 2011;18(suppl 2):191.
31.
Rubino A, Rousculp MD, Davis K, Wang J, Bastyr EJ, Tesfaye S: Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom. Prim Care Diabetes 2007;1:129-134.
32.
Truini A, Leonette FJ, De Toni Franceshini L, Zanette G, Praitano M, Schenone A, et al: Prevalence of peripheral neuropathies and neuropathic pain in patients with diabetes. Preliminary results of an Italian multicenter study. J Peripher Nerv Syst 2011;16(suppl):S36-S37.
33.
Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM: Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-213.
34.
Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S: Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Curr Med Res Opin 2007;23:2035-2042.
35.
Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A: Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2009;13:582-587.
36.
Davies M, Brophy S, Williams R, Taylor A: The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-1522.
37.
Olsen BS, Sjølie A, Hougaard P, Johannesen J, Borch-Johnsen K, Marinelli K, Thorsteinsson B, Pramming S, Mortensen HB: A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications 2000;14:295-300.
38.
Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ 3rd, Service FJ: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824.
39.
Fujimoto WY, Leonetti DL, Kinyoun JL, Shuman WP, Stolov WC, Wahl PW: Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance. Diabetes 1987;36:730-739.
40.
Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C: Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380—387.
41.
Torrance N, Smith BH, Bennett MI, Lee AJ: The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-289.
42.
Dieleman JP, Kerklaan J, Huygen FJPM, Bouma PA D, Sturkenboom MC: Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008;137:681-688.
43.
Hall GC, Carroll D, McQuay HJ: Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract 2008;9:26.
44.
Hall GC, Carroll D, Parry D, McQuay HJ: Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156-162.
45.
Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-1486.
46.
Watanabe K, Hagura R, Akanuma Y, Takasu T, Kajinuma H, Kuzuya N, Irie M: Characteristics of cranial nerve palsies in diabetic patients. Diabetes Res Clin Pract 1990;10:19-27.
47.
O'Hare JA, Abuaisha F, Geoghegan M: Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 1994;163:132-135.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.